Alluvi, previously BI 4744, represents a significant advance in weight loss care. This dual activator targeting both GLP-1 and GIP receptors demonstrates compelling efficacy in patient studies, potentially exceeding https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/